New clinical data highlight advancements in immunotherapy for lung cancers. BioNTech and Bristol Myers Squibb reported promising Phase 2 results combining PD-L1xVEGF dual-action drug pumitamig with chemotherapy in small cell lung cancer, showing tumor shrinkage in 76% of patients. Meanwhile, Merck and Daiichi Sankyo's antibody-drug conjugate ifinatamab deruxtecan achieved a 48.2% response rate in a phase II study for extensive-stage small-cell lung cancer. However, Summit Therapeutics’ ivonescimab showed progression-free survival benefits but failed to demonstrate overall survival improvement in a global Phase 3 trial, complicating its FDA approval prospects.